Get started
Author

Maria-Anna Chrysovergi

Observed name: M.-A. Chrysovergi
ORCID: 0009-0007-4139-4666
Observed ORCID: 0009-0007-4139-4666
OpenAlex ID: A5088569576
Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer
2025 · Taslim A. Al-Hilal, Maria-Anna Chrysovergi, et al. · Nature Cell Biology · 33
Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B
2024 · Hope A. Flaxman, Maria-Anna Chrysovergi, et al. · JCI Insight · 13
Ephrin-B2 Neutralizing Antibody Suppresses the SASP in Senescent Fibroblasts and Treats Lung Fibrosis in Aged Mice
2022 · R. Lister, M.-A. Chrysovergi, et al. · American Journal of Respiratory and Critical Care Medicine · 2
Quantitative gene-level inference of tumor transcription from plasma epigenomes
2026 · Matthew Freedman, Gunsagar Gulati, et al. · Research Square
PDF
α TAT1 defines a microtubule mechanosensing axis that drives fibroblast durotaxis and fibrosis across organs
2025 · Alba Santos, Tamanna Islam, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract PS14-07: Spatial transcriptomics of matched breast cancer brain metastases and primary tumors identifies a brain-specific immune-suppressive transcriptional program
2025 · Patrick Kurnia, Sheheryar Kabraji, et al. · Clinical Cancer Research
Durotaxis in Lung Fibrosis: Transitioning from In Vitro Mechanisms to In Vivo Imaging
2022 · I. Ganzleben, M.-A. Chrysovergi, et al. · American Journal of Respiratory and Critical Care Medicine
Bloodworm (Glycera dibranchiata Ehlers, 1868) Populations in the Gulf of Maine AreConnected Through Gene Flow
2020 · LM Williams, Anna Marie Bowsher, et al. · SCARAB (Bates College)
Works count: 8
Citation count: 48
H-index: 2
I10-index: 2
Year
Topic
Type